FDA Committee Endorses Amgen’s Postmenopausal Osteoporosis BLA, Recommends Black Box

Drug Industry Daily
A A
An FDA advisory committee on Wednesday approved the risk-benefit profile of Amgen’s romosozumab, a monoclonal antibody for treatment of osteoporosis.

To View This Article:

Login

Subscribe To Drug Industry Daily